Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Immune-related adverse events
•
Neurology
•
Neuromuscular
How do you manage immunotherapy-induced myasthenia gravis?
Answer from: at Academic Institution
My go-to algorithm is well-represented in the paper by Dr. @Adeel Zubair et al. Zubair et al., PMID 36439604
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
NCCN "Management of Immunotherapy-Related Toxicities" has a useful 'cheat sheet' as a quick reference for the overnight call.
Sign in or Register to read more
19074
19390
Related Questions
How does one interpret an SPEP showing potentially obscured but non-quantifiable M-spike however an IFE showing monoclonal protein?
At what point do you consider weaning steroids or immuno-modulating agents in patients with Myasthenia Gravis?
How do you dose gabapentin in patients with renal failure?
Beyond fatigability, what distinctive features of diplopia characterize myasthenia gravis?
What is the stepwise investigation of patients suspected of inflammatory myopathy?
How do you use muscle MRI in the diagnosis and management of muscular dystrophies?
What postural change in FVC is suggestive of respiratory muscle weakness?
How do you reconcile the benefits of high glycemic load to slow ALS disease progression with previous data on the increased risk for ALS associated with diabetes mellitus?
How do you treat benign fasciculation syndrome?
Is there a role for intravenous temozolomide in place of oral for the 5-day dosing q 28 days after surgery/XRT+Temozolomide for glioblastoma multiforme?